Patent Lawsuit Targets JUUL2
Days After FDA Authorization
AJ Marketing LLC sues JUUL Labs in federal court over JUUL2 pods & device — just six days after the FDA granted marketing authorization
JUUL Labs had barely finished celebrating a landmark regulatory victory when a fresh legal challenge arrived. Less than a week after securing FDA marketing authorization for its JUUL2 device and JUUL2 pods, the company found itself back in federal court — this time defending against a patent infringement claim that could reshape its U.S. commercial strategy.
JUUL Labs had barely finished celebrating a major regulatory victory before another legal challenge arrived. On August 28, 2026, the U.S. Food and Drug Administration announced marketing authorization for three JUUL2 products through the PMTA pathway. Less than a week later, on September 3, 2026, AJ Marketing LLC filed a federal patent infringement lawsuit against JUUL Labs Inc. in the U.S. District Court for the District of Delaware.
The lawsuit alleges that both the original JUUL and the newly authorized JUUL2 platform infringe U.S. Patent No. 8,851,068, titled Personal Inhalation Devices. The timing makes the dispute especially significant — JUUL2 represents an important part of JUUL's attempt to rebuild its position in the regulated U.S. vaping market, and this challenge arrived almost immediately after securing federal marketing authorization for JUUL2 pods and the JUUL2 device.
Important: These are allegations in an active lawsuit. Filing a patent infringement complaint does not establish infringement. No court has ruled on the merits of AJ Marketing's claims. JUUL2 remains FDA authorized and can be legally marketed in the United States.
JUUL2 Patent Lawsuit: Key Facts at a Glance
| Detail | Information |
|---|---|
| Plaintiff | AJ Marketing LLC |
| Defendant | JUUL Labs Inc. |
| Court | U.S. District Court for the District of Delaware |
| Case Number | 1:26-cv-01110 |
| Lawsuit Filed | September 3, 2026 |
| Patent at Issue | U.S. Patent No. 8,851,068 |
| Patent Title | Personal Inhalation Devices |
| Products Named | Original JUUL device and JUUL2 platform |
| FDA Authorization | August 28, 2026 |
| Legal Basis | 35 U.S.C. § 271 (Patent Infringement) |
| Jury Trial Demanded | Yes — requested by AJ Marketing |
| Patent Estimated Expiry | Approximately January 2031 |
| Current Status | Early stage — no court ruling made |
JUUL2 FDA Authorization: What the FDA Decided
The JUUL2 FDA authorization announced on August 28, 2026 cleared three specific products for legal marketing in the United States through the Premarket Tobacco Product Application (PMTA) process:
- JUUL2 Device — next-generation closed-pod system designed for adult smokers (21+)
- JUUL2 Virginia Tobacco 18 mg/mL pods — classic tobacco flavor
- Polar Menthol JUUL2 pods — crisp menthol flavor
The FDA's scientific review found that adult cigarette smokers significantly switched away from combustibles when using JUUL2. Complete switching rates at six weeks ranged from 19.9% to 34.6% for Virginia Tobacco pod users, and 28.4% to 49.3% for Polar Menthol pod users. The agency concluded these benefits to adult smokers outweighed population-level risks.
This decision brought the total FDA-authorized e-cigarette count to 48 products. JUUL originally secured FDA authorization for its first-generation device and JUULpods in July 2025.
FDA Authorized ≠ FDA Approved. JUUL2 is authorized for marketing — not technically "FDA approved." The FDA's order explicitly prohibits JUUL from making that claim. Authorization means marketing is appropriate for public health protection under federal tobacco law, not that the products are safe or recommended for non-smokers.
U.S. Patent No. 8,851,068 — What It Covers
At the center of the JUUL2 patent lawsuit is U.S. Patent No. 8,851,068, titled Personal Inhalation Devices. The application was filed in 2010 and the patent was issued on October 7, 2014 — years before JUUL became the dominant name in the American pod-vape category.
The patent describes a personal inhalation device built around three core components:
- Reservoir — a container holding a deliverable substance such as a nicotine-containing liquid
- Atomizing Unit — a heating element that vaporizes the substance for inhalation
- Electronic Control System — a system for controlling or metering delivery, including sensors, processors, and power management
Although the patent's technology was originally conceived around delivering metered caffeine doses, its language is substantially broader. It explicitly covers a variety of deliverable substances, including nicotine. AJ Marketing uses that breadth to extend its claims to JUUL's e-cigarette products.
Because Patent No. 8,851,068 predates JUUL's entry into the market, AJ Marketing's position is that the fundamental inhalation technology JUUL built its business on was already covered by existing intellectual property. Bloomberg Law estimates the patent remains in force until approximately January 2031.
Industry context: A patent covering broad inhalation device architecture could, depending on how courts interpret the claims, reach beyond JUUL to other manufacturers whose products incorporate a similar reservoir-atomizer-control design — which describes most modern pod-based vaping systems.
AJ Marketing vs. JUUL Labs — What the Lawsuit Claims
According to the federal court docket, AJ Marketing LLC filed its complaint on September 3, 2026, alleging patent infringement under 35 U.S.C. § 271 and demanding a jury trial. The lawsuit covers both the original JUUL device and the newly authorized JUUL2 platform.
What AJ Marketing Is Seeking From JUUL
- Past damages (reasonable royalties) — compensation covering the six years of alleged infringement prior to the lawsuit filing date
- Ongoing royalties (future damages) — continuing royalties for any future use of the patented technology if the court finds infringement
- Potential injunction — AJ Marketing may seek a court order stopping further alleged infringement; this is conditional on a finding of infringement, which has not occurred
- Jury trial — AJ Marketing has formally requested that a jury decide the case
Key point: The primary reported relief is financial compensation — royalties — not a ban on JUUL2 sales. This is how most patent disputes resolve: through licensing agreements or royalty payments rather than product removal.
JUUL has several defensive options: dispute how the patent claims are interpreted, argue its products do not practice the claimed inventions, challenge the validity of the patent itself, or a combination of all three. None of those issues have been determined yet.
FDA Authorization vs. Patent Rights: Two Separate Systems
| FDA Authorization | Patent Rights |
|---|---|
| Determines whether a tobacco product can be legally marketed under federal tobacco law | Protects an inventor's right to exclude others from using patented technology |
| Administered by: FDA Center for Tobacco Products (CTP) | Administered by: USPTO; enforced through federal courts |
| Process: PMTA scientific review | Process: Patent litigation in federal district court |
| Receiving authorization does NOT grant immunity from patent lawsuits | Filing a patent lawsuit does NOT revoke FDA marketing authorization |
Could the Patent Lawsuit Stop JUUL2 Sales?
At this stage, there is no basis to say JUUL2 has been removed from the U.S. market because of the lawsuit. The filing of a patent infringement complaint does not automatically stop sales or trigger any product recall.
A patent lawsuit does not automatically stop JUUL2 sales. The product remains legally on the market with FDA marketing authorization.
Filing of the lawsuit does not cancel or revoke the FDA's marketing authorization granted August 28, 2026.
FDA authorization does not grant immunity from patent litigation. These are entirely separate legal processes.
In rare cases a court could issue an injunction — but only after finding infringement. That has not happened here.
JUUL2 pods and the JUUL2 device remain among the FDA's 48 authorized e-cigarette products. Retailers should rely on the official FDA database — not litigation headlines — when determining a product's regulatory status.
What the JUUL2 Lawsuit Means for Vape Retailers
- JUUL2 can still be sold. JUUL2 is FDA authorized for marketing in the U.S. The lawsuit does not change that status at this stage.
- Monitor legal developments. Future court rulings could potentially lead to an injunction affecting sales — though no such outcome has occurred.
- Maintain authorized supplier relationships. Continue working with legitimate distributors as the case develops.
- Plan for possible changes. Damages, royalties, or licensing requirements resulting from the case may eventually affect JUUL's pricing or distribution agreements.
- Always verify FDA status. Check the official FDA database rather than media reports to confirm authorization status of any vaping product.
JUUL2 Patent Lawsuit Timeline: Key Dates & What's Ahead
Patent No. 8,851,068 Issued
Personal Inhalation Devices patent issues — covering technology for inhalation devices that deliver substances including nicotine.
Original JUUL Receives FDA Authorization
The FDA authorized several original JUUL products including the JUUL Device and tobacco/menthol JUULpods.
JUUL2 FDA Authorization Announced
The FDA grants marketing authorization for the JUUL2 Device, Virginia Tobacco JUUL2 pods, and Polar Menthol JUUL2 pods through the PMTA pathway.
Patent Lawsuit Filed — Case No. 1:26-cv-01110
AJ Marketing LLC files patent infringement lawsuit against JUUL Labs Inc. in the U.S. District Court for the District of Delaware, alleging both JUUL and JUUL2 infringe Patent No. 8,851,068.
JUUL Responds to Complaint
JUUL Labs files its official answer to AJ Marketing's allegations — potentially denying infringement, challenging patent validity, or filing counterclaims.
Discovery Phase
Both parties exchange evidence including technical documents, engineering data, and expert testimony. Claim construction — where the court defines the scope of the patent — is a pivotal milestone.
Court Proceedings / Possible Settlement
The court addresses patent validity, claim interpretation, and infringement. Many patent cases resolve through settlement before trial, potentially via a licensing agreement or royalty deal.
Trial (If No Settlement)
A judge or jury determines whether JUUL infringed Patent No. 8,851,068 and what damages, if any, are owed. A ruling could significantly impact JUUL2's U.S. commercial position.
What Happens Next in the JUUL2 Patent Lawsuit?
The case is at an early stage. Several paths are possible from here:
The parties reach an agreement outside of court — a licensing deal or royalty arrangement. Many patent disputes resolve this way before trial.
A court finds infringement and awards AJ Marketing financial compensation and/or ongoing royalties on JUUL2 sales.
JUUL successfully defeats the infringement claims — potentially by invalidating the patent or proving its products do not practice the claimed inventions.
In an unlikely outcome, a court issues an injunction limiting JUUL2 sales — only possible after a finding of infringement, not at this stage.
Frequently Asked Questions
The case is at an early stage. Several paths are possible from here:
The parties reach an agreement outside of court — a licensing deal or royalty arrangement. Many patent disputes resolve this way before trial.
A court finds infringement and awards AJ Marketing financial compensation and/or ongoing royalties on JUUL2 sales.
JUUL successfully defeats the infringement claims — potentially by invalidating the patent or proving its products do not practice the claimed inventions.
In an unlikely outcome, a court issues an injunction limiting JUUL2 sales — only possible after a finding of infringement, not at this stage.